


IN THE UNITED STATES DISTRICT COURT  
FOR THE NORTHERN DISTRICT OF TEXAS  
AMARILLO DIVISION



ALLIANCE FOR HIPPOCRATIC  
MEDICINE, *et al.*,

Plaintiffs,

v.

U.S. FOOD AND DRUG  
ADMINISTRATION, *et al.*,

Defendants.

§  
§  
§  
§  
§  
§  
§  
§  
§  
§  
§

2:22-CV-0223-Z

**ORDER**

On February 6, 2023, the Court granted Danco Laboratories, LLC's ("Danco") motion for to intervene. ECF No. 33. The Court subsequently extended Plaintiffs' deadline to reply to February 24 to afford Plaintiffs more time to consider Danco's response to the motion for preliminary injunction. *See* ECF No. 43. Plaintiffs misconstrued the Court's order as permitting two replies — one to the response by the U.S. Food and Drug Administration *et al.* ("FDA") and one to the response by Danco. On February 10, Plaintiffs filed their reply to the FDA's response only. The Court hereby **ORDERS**: On or before February 24, 2023, Plaintiffs may file one Reply that consolidates (1) Plaintiffs' reply to the FDA's response (ECF No. 28) *and* (2) Plaintiffs' reply to Danco's Response (ECF No. 50). The Court therefore **STRIKES** Plaintiffs' reply (ECF Nos. 76, 79) without prejudice to Plaintiffs re-filing a reply in accordance with this order.

**SO ORDERED.**

February 13, 2023

MATTHEW J. KACSMARYK  
UNITED STATES DISTRICT JUDGE